Company intelligence / Profile preview

SingulOmics

New York, New York, United States

Ownership: Private
Employees: ~16
Development stage: Other

Overview

SingulOmics offers commercial single-cell and spatial omics services, including proprietary AccuSomatic Amplification technology for high-accuracy detection of somatic single nucleotide variations and other advanced genomics, transcriptomics, and epigenomics assays. Clients include research institutions and biopharma companies. No pipeline of proprietary therapeutics; main focus is on service provision, including several peer-reviewed publications supporting validity of their technology.

Therapeutic areas: OncologyOtherRare Diseases
Modalities: Genomic sequencingProteomicsTranscriptomicsEpigenomicsSpatial transcriptomics
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on SingulOmics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SingulOmics.

Explore the full profile